Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis

Authors: Andrea Malfettone, Concetta Saponaro, Angelo Paradiso, Giovanni Simone, Annita Mangia

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Traditional determinants proven to be of prognostic importance in breast cancer include the TNM staging, histological grade, proliferative activity, hormone receptor status and HER2 overexpression. One of the limitations of the histological grading scheme is that a high percentage of breast cancers are still classified as grade 2, a category with ambiguous clinical significance. The aim of this study was to best characterize tumors scored as grade 2.

Methods

We investigated traditional prognostic factors and a panel of tumor markers not used in routine diagnosis, such as NHERF1, VEGFR1, HIF-1α and TWIST1, in 187 primary invasive breast cancers by immunohistochemistry, stratifying patients into good and poor prognostic groups by the Nottingham Prognostic Index.

Results

Grade 2 subgroup analysis showed that the PVI (p = 0.023) and the loss of membranous NHERF1 (p = 0.028) were adverse prognostic factors. Relevantly, 72% of grade 2 tumors were associated to PVI+/membranous NHERF1- expression phenotype, characterizing an adverse prognosis (p = 0.000). Multivariate logistic regression analysis in the whole series revealed poor prognosis correlated with PVI and MIB1 (p = 0.000 and p = 0.001, respectively). Furthermore, in the whole series of breast cancers we found cytoplasmic NHERF1 expression positively correlated to VEGFR1 (r = 0.382, p = 0.000), and in VEGFR1-overexpressing tumors the oncogenic receptor co-localized with NHERF1 at cytoplasmic level.

Conclusions

The PVI+/membranous NHERF1- expression phenotype identifies a category of grade 2 tumors with the worst prognosis, including patient subgroup with a family history of breast cancer. These observations support the idea of the PVI+/membranous NHERF1- expression immunophenotype as a useful marker, which could improve the accuracy of predicting clinical outcome in grade 2 tumors.
Appendix
Available only for authorised users
Literature
1.
Mangia A, Malfettone A, Simone G, Darvishian F: Old and new concepts in histopathological characterization of familial breast cancer. Ann Oncol. 2011, 22 (Suppl 1): i24-i30.CrossRefPubMed
2.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. the value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. elston & I. O. ellis. Histopathology. 1991, 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x. Histopathology. 2002 Sep;41(3A):151,2, discussion 152-3CrossRefPubMed
3.
Galea MH, Blamey RW, Elston CE, Ellis IO: The nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat. 1992, 22 (3): 207-219. 10.1007/BF01840834.CrossRefPubMed
4.
Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, et al: Prognostic significance of nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008, 26 (19): 3153-3158. 10.1200/JCO.2007.15.5986.CrossRefPubMed
5.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. the value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 1991, 19 (5): 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed
6.
Ignatiadis M, Sotiriou C: Understanding the molecular basis of histologic grade. Pathobiology. 2008, 75 (2): 104-111. 10.1159/000123848.CrossRefPubMed
7.
Blamey RW: The design and clinical use of the Nottingham Prognostic Index in breast cancer. Breast. 1996, 5: 156-157. 10.1016/S0960-9776(96)90064-8.CrossRef
8.
Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, et al: A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 2005, 65 (10): 4059-4066. 10.1158/0008-5472.CAN-04-3953.CrossRefPubMed
9.
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006, 98 (4): 262-272. 10.1093/jnci/djj052.CrossRefPubMed
10.
Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, Van't Veer L, et al: Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics. 2008, 9: 394-10.1186/1471-2164-9-394.CrossRefPubMedPubMedCentral
11.
Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, et al: A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res. 2008, 14 (9): 2601-2608. 10.1158/1078-0432.CCR-07-5026.CrossRefPubMed
12.
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al: Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10 (4): R65-10.1186/bcr2124.CrossRefPubMedPubMedCentral
13.
Bonnefoi H, Underhill C, Iggo R, Cameron D: Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic?. Eur J Cancer. 2009, 45 (10): 1733-1743. 10.1016/j.ejca.2009.04.036.CrossRefPubMed
14.
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009, 101 (10): 736-750. 10.1093/jnci/djp082.CrossRefPubMedPubMedCentral
15.
Abdel-Fatah TM, Powe DG, Ball G, Lopez-Garcia MA, Habashy HO, Green AR, et al: Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. J Pathol. 2010, 222 (4): 388-399. 10.1002/path.2775.CrossRefPubMed
16.
Volpi A, Bacci F, Paradiso A, Saragoni L, Scarpi E, Ricci M, et al: Prognostic relevance of histological grade and its components in node-negative breast cancer patients. Mod Pathol. 2004, 17 (9): 1038-1044. 10.1038/modpathol.3800161.CrossRefPubMed
17.
Mangia A, Chiriatti A, Bellizzi A, Malfettone A, Stea B, Zito FA, et al: Biological role of NHERF1 protein expression in breast cancer. Histopathology. 2009, 55 (5): 600-608. 10.1111/j.1365-2559.2009.03424.x.CrossRefPubMed
18.
Bellizzi A, Malfettone A, Cardone RA, Mangia A: NHERF1/EBP50 in breast cancer: clinical perspectives. Breast Care (Basel). 2010, 5 (2): 86-90. 10.1159/000298962.CrossRef
19.
Mangia A, Malfettone A, Saponaro C, Tommasi S, Simone G, Paradiso A: Human epidermal growth factor receptor 2, na(+)/H(+) exchanger regulatory factor 1, and breast cancer susceptibility gene-1 as new biomarkers for familial breast cancers. Hum Pathol. 2011, 42 (11): 1589-1595. 10.1016/j.humpath.2011.01.010.CrossRefPubMed
20.
Cardone RA, Casavola V, Reshkin SJ: The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer. 2005, 5 (10): 786-795. 10.1038/nrc1713.CrossRefPubMed
21.
Lee TH, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, et al: Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 2007, 4 (6): e186-10.1371/journal.pmed.0040186.CrossRefPubMedPubMedCentral
22.
Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, et al: Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, tie-2/Tek and CD105 expression in breast cancer (n = 905). Br J Cancer. 2004, 90 (6): 1216-1221. 10.1038/sj.bjc.6601452.CrossRefPubMedPubMedCentral
23.
Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004, 117 (7): 927-939. 10.1016/j.cell.2004.06.006.CrossRefPubMed
24.
Foubert E, De Craene B, Berx G: Key signalling nodes in mammary gland development and cancer. the Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res. 2010, 12 (3): 206-10.1186/bcr2585.CrossRefPubMedPubMedCentral
25.
Mangia A, Chiriatti A, Tommasi S, Menolascina F, Petroni S, Zito FA, et al: BRCA1 expression and molecular alterations in familial breast cancer. Histol Histopathol. 2009, 24 (1): 69-76.PubMed
26.
Sobin LH, Hermanek P, Hutter RV: TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer. 1988, 61 (11): 2310-2314. 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X.CrossRefPubMed
27.
Mangia A, Tommasi S, Bruno M, Malfettone A, D'Amico C, Zito FA, et al: Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer. Oncol Rep. 2010, 23 (6): 1641-1645.CrossRefPubMed
28.
Du Toit RS, Locker AP, Ellis IO, Elston CW, Blamey RW: Evaluation of the prognostic value of triple node biopsy in early breast cancer. Br J Surg. 1990, 77 (2): 163-167. 10.1002/bjs.1800770216.CrossRefPubMed
29.
Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E: Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology. 2005, 46 (1): 31-36. 10.1111/j.1365-2559.2005.02045.x.CrossRefPubMed
30.
Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, Latorre A, et al: Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol. 2005, 16 (Suppl 4): iv14-iv19.PubMed
31.
Cardone RA, Bellizzi A, Busco G, Weinman , Dell'Aquila ME, Casavola V, et al: The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell. 2007, 18 (5): 1768-1780. 10.1091/mbc.E06-07-0617.CrossRefPubMedPubMedCentral
32.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005, 365 (9472): 1687-1717.CrossRef
33.
Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, et al: Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat. 2008, 110 (3): 465-475. 10.1007/s10549-007-9742-1.CrossRefPubMed
34.
Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L, et al: Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell. 2011, 19 (3): 372-386. 10.1016/j.ccr.2011.01.036.CrossRefPubMedPubMedCentral
35.
Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ: Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol. 2005, 16 (11): 1723-1739. 10.1093/annonc/mdi352.CrossRefPubMed
36.
Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR: MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat. 2011, 127 (3): 591-599. 10.1007/s10549-010-1028-3.CrossRefPubMed
37.
Ediger TR, Kraus WL, Weinman EJ, Katzenellenbogen BS: Estrogen receptor regulation of the Na+/H+ exchange regulatory factor. Endocrinology. 1999, 140 (7): 2976-2982. 10.1210/en.140.7.2976.PubMed
38.
Maudsley S, Zamah AM, Rahman N, Blitzer JT, Luttrell LM, Lefkowitz RJ, et al: Platelet-derived growth factor receptor association with na(+)/H(+) exchanger regulatory factor potentiates receptor activity. Mol Cell Biol. 2000, 20 (22): 8352-8363. 10.1128/MCB.20.22.8352-8363.2000.CrossRefPubMedPubMedCentral
39.
Lazar CS, Cresson CM, Lauffenburger DA, Gill GN: The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface. Mol Biol Cell. 2004, 15 (12): 5470-5480. 10.1091/mbc.E04-03-0239.CrossRefPubMedPubMedCentral
40.
Bachelder RE, Wendt MA, Mercurio AM: Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 2002, 62 (24): 7203-7206.PubMed
41.
Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al: Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010, 12 (4): 207-PubMedPubMedCentral
42.
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005, 16 (10): 1569-1583. 10.1093/annonc/mdi326.CrossRefPubMed
43.
Mohammed RA, Martin SG, Mahmmod AM, Macmillan RD, Green AR, Paish EC, et al: Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. J Pathol. 2011, 223 (3): 358-365. 10.1002/path.2810.CrossRefPubMed
44.
Mohammed RA, Ellis IO, Mahmmod AM, Hawkes EC, Green AR, Rakha EA, et al: Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Mod Pathol. 2011, 24 (6): 774-785. 10.1038/modpathol.2011.4.CrossRefPubMed
45.
Sabatier R, Jacquemier J, Bertucci F, Esterni B, Finetti P, Azario F, et al: Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome. Eur J Cancer. 2011, 47 (10): 1537-1545. 10.1016/j.ejca.2011.02.002.CrossRefPubMed
46.
Georgescu MM, Morales FC, Molina JR, Hayashi Y: Roles of NHERF1/EBP50 in cancer. Curr Mol Med. 2008, 8 (6): 459-468. 10.2174/156652408785748031.CrossRefPubMed
Metadata
Title
Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis
Authors
Andrea Malfettone
Concetta Saponaro
Angelo Paradiso
Giovanni Simone
Annita Mangia
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-106

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Brain metastases from hepatocellular carcinoma: clinical features and prognostic factors

Research article

Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma

Research article

Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventh edition of the AJCC staging system

Research article

PTENgenomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity

Research article

Disruption of CTCF at the miR-125b1 locus in gynecological cancers

Research article

Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits